SCHEMBL10120096

SCHEMBL10120096

Cc1cccc(C)c1N1CCN(C(=O)CNc2c(-c3ccc(N4CCCC4)cc3)nc3ccccn23)CC1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 8/20 0.50
MAPT P10636 5/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
TP53 P04637 3/20 0.50
KDM4E B2RXH2 5/20 0.49
ALDH1A1 P00352 4/20 0.49
HPGD P15428 3/20 0.49
HSD17B10 Q99714 2/20 0.49
TSHR P16473 1/20 0.49
ALOX5 P09917 1/20 0.46
ADORA1 P30542 1/20 0.41
KCNK3 O14649 3/20 0.41
KCNK9 Q9NPC2 3/20 0.41
RXFP1 Q9HBX9 2/20 0.40
NTRK1 P04629 2/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
PKM P14618 1/20 0.40
TOP2A P11388 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10120622 0.91 GAA (0.50) GAAMAPTSMN1; SMN2TP53KDM4E
SCHEMBL10120421 0.91 MAPT (0.48) GAAMAPTSMN1; SMN2TP53KDM4E
SCHEMBL15179462 0.90 ALOX5 (0.46) GAAMAPTSMN1; SMN2TP53KDM4E
SCHEMBL10120315 0.88 MAPT (0.49) GAAMAPTSMN1; SMN2TP53KDM4E
SCHEMBL10120310 0.86 GAA (0.49) GAAMAPTSMN1; SMN2TP53KDM4E
SCHEMBL10120425 0.86 ALOX5 (0.45) GAAMAPTSMN1; SMN2TP53KDM4E
SCHEMBL10120305 0.85 ALDH1A1 (0.45) GAAMAPTSMN1; SMN2TP53KDM4E
SCHEMBL15179288 0.85 ALOX5 (0.47) GAAMAPTSMN1; SMN2TP53KDM4E
SCHEMBL10120319 0.85 GAA (0.45) GAAMAPTSMN1; SMN2TP53KDM4E
SCHEMBL10120619 0.84 ALOX5 (0.46) GAAMAPTSMN1; SMN2TP53KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2601194-B1 FUSED-IMIDAZOYL COMPOUNDS USEFUL AS ANTIMICROBIAL AGENTS MERCK SHARP & DOHME (US) 2016-05-25 EP disclosed
US-8871929-B2 Fused-imidazoyl compounds useful as antimicrobial agents MERCK SHARP & DOHME CORP. (US) 2014-10-28 US disclosed
US-8871929-B2 Fused-imidazoyl compounds useful as antimicrobial agents MERCK SHARP & DOHME CORP. (US) 2014-10-28 US disclosed
US-20130210816-A1 FUSED-IMIDAZOYL COMPOUNDS USEFUL AS ANTIMICROBIAL AGENTS MERCK SHARP & DOHME LLC 2013-08-15 US disclosed
US-20130210816-A1 FUSED-IMIDAZOYL COMPOUNDS USEFUL AS ANTIMICROBIAL AGENTS MERCK SHARP & DOHME LLC 2013-08-15 US disclosed
WO-2012018662-A2 FUSED-IMIDAZOYL COMPOUNDS USEFUL AS ANTIMICROBIAL AGENTS SCHERING CORPORATION (US) 2012-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130210816-A1 FUSED-IMIDAZOYL COMPOUNDS USEFUL AS ANTIMICROBIAL AGENTS MRPL21, ARG1, RPS4Y1 GAA 2781/4885MAPT 4607/4885SMN1; SMN2 3731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.